BIJOY TELIVALA, MD

BIOGRAPHY

Dr. Bijoy Telivala is board-certified in medical oncology, hematology and internal medicine, and practices at our Southside location. Originally from India, Dr. Telivala received his Bachelor of Medicine and Bachelor of Surgery from Lokmanya Tilak Municipal Medical College in Mumbai. He received his Doctor of Medicine from  Temple University in Philadelphia, Pennsylvania and remained at Temple University/Fox Chase Cancer Center  to complete his fellowship in Hematology and Oncology

Aside from his love for his patients and patient-care, Dr. Telivala finds the oncology/hematology field incredibly motivating: “we push the limit every day in terms of medical care and quality of life.  We are seeing new developments at a very rapid pace,” he says. “A cancer diagnosis is life changing for everyone associated with the patient, so I believe that the best care is about evaluating and helping, not just the patient, but the entire family – everyone and everything needs to be taken into consideration.”

During his time in medicine, Dr. Telivala has learned to listen and talk with his patients: “I have learned to become their guide, friend, and advocate on this difficult journey, including picking up subtle clues of things they want to say but are unable to,” he says, continuing “each patient is unique and I have learned to respect each of them.”

Dr. Telivala enjoys working with a group of doctors, nurses, and other support staff who share the primary goal of helping and guiding patients: “the compassion and empathy offered by the team as CSNF is truly unmatched.”

When not at work, Dr. Telivala enjoys spending time with his wife and daughter, and playing table tennis and bridge.

Curriculum Vitae

BOARD CERTIFICATIONS

Hematology

Internal Medicine

Medical Oncology

PROFESSIONAL ASSOCIATIONS

American Society of Clinical Oncology

American Society of Hematology

Pennsylvania Medical Society

Indian Medical Association

FELLOWSHIP

Fox Chase Cancer Center, Temple University Hospital

Hematology/Oncology

RESIDENCY

Temple University

INTERNSHIP

Temple University

EDUCATION

Temple University

Doctor of Medicine

Lokmanya Tilak Municipal Medical College

Bachelor of Medicine & Bachelor of Surgery

HONORS AND AWARDS

2000

Honors in Internal Medicine

2000

Honors in Obstetrics & Gynecology

2000

Winner of Indian Academy of Pediatrics Quiz

2000

Dr. B.R.Damle Award in Medicine

1999

Honors in Pathology

1999

Dr. Phadkes Award in Pharmacology

1997

Honors in Biochemistry

1997

Honors in Physiology

RESEARCH (Principal Investigator Responsibilities)

NCT: N/A

Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer, Phase: N/A, Non-interventional

NCT: N/A

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study, Phase: N/A, Non-interventional

NCT02743494

A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer, Phase: III, Interventional

NCT02582879

informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia, Phase: IV, Non-interventional

NCT03001882

An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in Combination with Ipilimumab in Subjects with Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC), Phase: II, Interventional

NCT02869789

A Phase 3b/4 Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer, Phase: III / IV, Interventional

NCT03036098

A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer, Phase: III, Interventional

NCT01358877

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants with Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY), Phase: III, Interventional

NCT01945775

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients with BRCA Mutation (EMBRACA Study), Phase: III, Interventional

NCT02252159

Prospective Observational Study of Patients with Polycythemia Vera in US Clinical Practices (REVEAL) Phase: IV, Non-interventional

NCT02008227

A Study of Atezolizumab Compared With Docetaxel in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy (OAK), Phase: III, Interventional

NCT02125461

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC), Phase: III, Interventional

NCT02366143

A Study of Atezolizumab in Combination with Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants with Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower150), Phase: III, Interventional

NCT: N/A

Lung Cancer Molecular Profiling and Clinical Outcomes in US Community Oncology Practices, Phase: IV, Non-interventional

NCT03029780

An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma (CheckMate 800), Phase: II, Interventional

NCT01615068

An Observational Study in Patients with HER2 Positive Metastatic Breast Cancer (SystHERs Registry), Phase: IV, Non-interventional

NCT01745367

Tivozanib Hydrochloride in Combination with Paclitaxel Versus Placebo with Paclitaxel in Patients with Locally Recurrent or Metastatic Triple Negative Breast Cancer (BATON-BC), Phase: II, interventional

NCT01593228

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial, Phase: N/A, Interventional

NCT01369433

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols, Phase: N/A, Interventional

PUBLICATIONS

NCODA's Positive Quality Intervention in Action

"PQI in Action: ADCETRIS"

Oncolytics Today

"Coordinating Combination Regimens: A Primer on an Emerging Trend in Oncology"

Lung Cancer Journal

"Luminespib Plus Pemetrexed in Patients with Non-Squamous Non-Small Cell Lung Cancer"

Annals of Oncology, Volume 29

“A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC.”

ESMO 2019 Abstract

“Measures of functional status in adults aged ≥ 70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS.”

San Antonio Breast Cancer Symposium

“Quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer treated with palbociclib in real-world practice settings.”

Lung Cancer

“Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.”

Young Women with Neutropenia. Vol. 46 No.13

Consultant

Infections in Medicine. Vol.26 no.2.

“Emphysematous Pyelonephritis Caused by Pasteurella Multocida After Embolization for Renal Cell Cancer.”

Japanese Society of Medical Oncology

"CheckMate 592: A Phase 2 Exploratory Study of Biomarkers of Efficacy for 1L Nivolumab + Ipilimumab in Advanced NSCLC"